通过循环代谢物评估欧米茄-3多不和脂肪酸对炎症性肠病的影响:一个调解门德尔随机化研究
Xiaojing Jia1,2, Chunyan Hu1,2, Xueyan Wu1,2
1Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Metabolites
|October 27, 2023
概括
补充omega-3脂肪酸补充剂的方法
科学领域:
- 营养流行病学 营养流行病学
- 遗传流行病学遗传流行病学
- 胃肠病学 胃肠病学
背景情况:
- 关于omega-3多不和脂肪酸 (PUFA) 和炎症性肠病 (IBD) 风险存在相互矛盾的流行病学数据.
- 有限的研究已经探索了特定的omega-3成分对IBD的影响.
- 了解这些关系对于IBD预防和管理至关重要.
研究的目的:
- 调查不同欧米茄-3 PUFAs对IBD,克罗恩病 (CD) 和性结肠炎 (UC) 风险的因果关系.
- 确定特定的omega-3成分和潜在的介导途径,影响IBD风险.
- 为了阐明FADS2基因在欧米茄-3PUFA介导的IBD风险中的作用.
主要方法:
- 采用双样本的门德尔随机化 (MR) 方法.
- 使用的与omega-3PUFA水平相关的遗传变异 (总omega-3,alpha-linolenic酸,eicosapentaenoic酸 (EPA),docosahexaenoic酸 (DHA)).
- 评估了与IBD,CD和UC风险的关联,并检查了介导代谢物和基因局部化 (FADS2).
主要成果:
- 基因预测较高的EPA度与IBD风险降低有关 (OR0.78).
- 这种关联似乎是由较低水平的酸和胺代谢产物调解的.
- 有限的证据支持了总omega-3,alpha-linolenic acid或DHA对IBD风险的影响.
结论:
- 乙酸 (EPA) 被确定为一个关键的omega-3成分,可能降低IBD风险.
- 脂肪酸脱酶2 (FADS2) 基因可能会调解欧米茄-3 PUFA 对IBD的影响.
- 研究结果表明,针对性补充或以EPA为重点的饮食策略可能对IBD有益.
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
338
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
338
Inflammatory Bowel Disease IV: Pharmacological Management
134
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
134
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
148
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
148
Drugs for Treatment of Ulcerative Colitis in IBD
149
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
149
Inflammatory Bowel Disease I: Ulcerative Colitis
192
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
192
Irritable Bowel Syndrome I: Introduction
284
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
284


